Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$26.12 - $34.07 $13,060 - $17,035
-500 Reduced 10.64%
4,200 $143,000
Q1 2024

May 15, 2024

SELL
$26.64 - $40.31 $210,456 - $318,449
-7,900 Reduced 62.7%
4,700 $165,000
Q4 2023

Feb 14, 2024

SELL
$19.95 - $31.0 $756,105 - $1.17 Million
-37,900 Reduced 75.05%
12,600 $363,000
Q3 2023

Nov 14, 2023

BUY
$21.33 - $59.42 $908,657 - $2.53 Million
42,600 Added 539.24%
50,500 $1.16 Million
Q2 2023

Aug 14, 2023

SELL
$34.33 - $62.11 $308,970 - $558,990
-9,000 Reduced 53.25%
7,900 $452,000
Q1 2023

May 15, 2023

BUY
$26.01 - $48.69 $410,958 - $769,302
15,800 Added 1436.36%
16,900 $636,000
Q4 2022

Feb 14, 2023

BUY
$24.14 - $30.37 $26,554 - $33,407
1,100 New
1,100 $29,000

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $2.19B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.